Page last updated: 2024-10-31

mitoxantrone and Myelodysplastic Syndromes

mitoxantrone has been researched along with Myelodysplastic Syndromes in 39 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Research Excerpts

ExcerptRelevanceReference
"Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination chemotherapy associating fludarabine, mitoxantrone (MXN), and high-dose cytarabine (continuous infusion) for high-risk P glycoprotein (PGP)-negative myelodysplastic syndromes (MDS) (FAM protocol)."9.11A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. ( Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E, 2004)
" In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)."9.11Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005)
"A prospective, randomized, double-blind placebo-controlled trial was designed to evaluate the impact of granulocyte/macrophage-colony-stimulating factor (GM-CSF) on the efficacy of sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy (S-HAM) in adult patients with high-risk myelodysplastic syndromes (MDS)."9.09Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Fonatsch, C; Haase, D; Heinecke, A; Hiddemann, W; Hinrichs, HF; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1999)
"Fifty-nine patients who received mitoxantrone as part of adjuvant chemotherapy for breast cancer between 1986 and 1992 were studied to determine the incidence of t-AML and t-MDS."9.08Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. ( Cremin, P; Daly, PA; Flattery, M; McCann, SR, 1996)
"This large case-control study demonstrates that the risk of AML/MDS is much higher with mitoxantrone-based chemotherapy than with anthracyclines-based chemotherapy in a population of women recently treated for breast cancer."7.74Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. ( Clisant, S; Cutuli, B; de Vathaire, F; Delaloge, S; Fenaux, P; Hill, C; Le Deley, MC; Linassier, C; Shamsaldin, A; Suzan, F, 2007)
"Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML)."5.16Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. ( Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J, 2012)
"Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination chemotherapy associating fludarabine, mitoxantrone (MXN), and high-dose cytarabine (continuous infusion) for high-risk P glycoprotein (PGP)-negative myelodysplastic syndromes (MDS) (FAM protocol)."5.11A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. ( Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E, 2004)
" In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)."5.11Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005)
"A prospective, randomized, double-blind placebo-controlled trial was designed to evaluate the impact of granulocyte/macrophage-colony-stimulating factor (GM-CSF) on the efficacy of sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy (S-HAM) in adult patients with high-risk myelodysplastic syndromes (MDS)."5.09Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Fonatsch, C; Haase, D; Heinecke, A; Hiddemann, W; Hinrichs, HF; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1999)
"Fifty-nine patients who received mitoxantrone as part of adjuvant chemotherapy for breast cancer between 1986 and 1992 were studied to determine the incidence of t-AML and t-MDS."5.08Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. ( Cremin, P; Daly, PA; Flattery, M; McCann, SR, 1996)
"Thirty-one adult patients with high-risk myelodysplastic syndromes (MDS) were enrolled in a prospective randomized double-blind placebo-controlled trial evaluating the efficacy of sequential high-dose Ara C/mitoxantrone chemotherapy with or without GM-CSF."5.08S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Hiddemann, W; Hinrichs, H; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1997)
"This large case-control study demonstrates that the risk of AML/MDS is much higher with mitoxantrone-based chemotherapy than with anthracyclines-based chemotherapy in a population of women recently treated for breast cancer."3.74Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. ( Clisant, S; Cutuli, B; de Vathaire, F; Delaloge, S; Fenaux, P; Hill, C; Le Deley, MC; Linassier, C; Shamsaldin, A; Suzan, F, 2007)
" We report the case history of a patient with myelodyspasia occurring after neoadjuvant methotrexate, mitoxantrone and mitomycin C (triple M) chemotherapy with subsequent radiotherapy for locally advanced breast cancer."3.70Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy. ( Lowdell, CP; Partridge, SE, 1999)
"Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2."3.70Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. ( Ashley, S; Kuan, A; Kulkarni, S; Mehta, J; Mitchell, P; Powles, R; Powles, T; Saso, R; Swansbury, GJ; Treleaven, J, 2000)
"To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML)."3.69Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. ( Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F, 1995)
"Maintenance treatment also reduced minimal residual disease (detected by WT1 and CBFβ-MYH11) in five of eight evaluable patients."2.79Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. ( Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L, 2014)
"Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7."1.46Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. ( Al-Kali, A; Castro, J; Dueck, A; Ertz-Archambault, N; Finn, L; Foran, J; Gauthier, S; Kelemen, K; Kosiorek, H; Marino, R; Mesa, RA; Palmer, J; Sproat, LZ; Taylor, GE; Tibes, R, 2017)
"For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor."1.40Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. ( Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E, 2014)
"Treatment of acute promyelocytic leukemia (APL) with a combination of anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very high rates of complete remission and survival."1.35Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. ( Mellink, CH; Snijder, S; van der Lelie, H, 2008)
"From 1998 to 2001, 5 consecutive cases of AML/TMDS entered our hospital and achieved complete remission (CR) with continuous drip infusion of low-dose etoposide and low-dose Ara-C combined with mitoxantrone (MEtA regimen)."1.32[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)]. ( Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M, 2004)
"We report on a patient with Fanconi's anemia (FA) who developed a myelodysplastic syndrome (RAEB-T) with complex karyotypic abnormalities (trp 1q23q42, monosomy 20, trisomy 13) at the age of 28."1.30Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen. ( Haase, D; Hiddemann, W; Schoch, C; Verbeek, W; Wörmann, B, 1997)
"AMH resembling acute megakaryoblastic leukemia may be seen transiently after treatment of AML."1.28Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia. ( Farhi, DC; Rosenthal, NS, 1991)

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's15 (38.46)18.2507
2000's17 (43.59)29.6817
2010's7 (17.95)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rashidi, A1
Ali, AM1
Vij, KR1
Shanley, R1
Romee, R1
Cooley, SA1
Westervelt, P1
DiPersio, JF1
Miller, JS1
Weisdorf, DJ1
Ustun, C1
Boddu, PC1
Zeidan, AM1
Jaglal, MV1
Duong, VH1
Bello, CM1
Al Ali, NH1
Padron, E1
Fernandez, HF1
List, AF1
Lancet, JE1
Komrokji, RS1
Robak, T1
Wierzbowska, A1
Ferrero, D1
Crisà, E1
Marmont, F1
Audisio, E1
Frairia, C1
Giai, V1
Gatti, T1
Festuccia, M1
Bruno, B1
Riera, L1
Passera, R1
Boccadoro, M1
Ertz-Archambault, N1
Kosiorek, H1
Taylor, GE1
Kelemen, K1
Dueck, A1
Castro, J1
Marino, R1
Gauthier, S1
Finn, L1
Sproat, LZ1
Palmer, J1
Mesa, RA1
Al-Kali, A1
Foran, J1
Tibes, R1
Waterman, J1
Rybicki, L1
Bolwell, B1
Copelan, E1
Pohlman, B1
Sweetenham, J1
Dean, R1
Sobecks, R1
Andresen, S1
Kalaycio, M1
Kobbe, G2
Germing, U2
Aivado, M2
Zohren, F1
Schubert, D1
Strupp, C1
Pape, H1
Tenderich, G1
Körfer, R1
Storb, R1
Haas, R2
Schneider, P1
Greenberg, PL1
Lee, SJ1
Advani, R1
Tallman, MS1
Sikic, BI1
Letendre, L1
Dugan, K1
Lum, B1
Chin, DL1
Dewald, G1
Paietta, E2
Bennett, JM2
Rowe, JM4
Bolaños-Meade, J1
Guo, C1
Gojo, I1
Karp, JE1
Prébet, T1
Ducastelle, S1
Debotton, S1
Stamatoullas, A1
Deconinck, E1
Fruchart, C1
Gratecos, N4
Ifrah, N3
Dreyfus, F4
Fenaux, P5
Wattel, E4
Tsukaguchi, M1
Furukawa, Y1
Shibano, M1
Kitani, T1
McLaughlin, P1
Estey, E1
Glassman, A1
Romaguera, J1
Samaniego, F1
Ayala, A1
Hayes, K1
Maddox, AM1
Preti, HA1
Hagemeister, FB1
Au, WY1
Chan, LC1
Liang, R1
Kwong, YL1
Büchner, T3
Berdel, WE2
Schoch, C2
Haferlach, T1
Serve, HL1
Kienast, J1
Schnittger, S1
Kern, W1
Tchinda, J1
Reichle, A1
Lengfelder, E1
Staib, P1
Ludwig, WD1
Aul, C5
Eimermacher, H1
Balleisen, L3
Sauerland, MC1
Heinecke, A2
Wörmann, B4
Hiddemann, W5
Le Deley, MC1
Suzan, F1
Cutuli, B1
Delaloge, S1
Shamsaldin, A1
Linassier, C1
Clisant, S1
de Vathaire, F1
Hill, C1
Snijder, S1
Mellink, CH1
van der Lelie, H1
Guerci, A4
Merlin, JL1
Missoum, N1
Feldmann, L1
Marchal, S1
Witz, F1
Rose, C1
Guerci, O1
Knauf, WU2
Ho, AD2
Kreuser, ED1
Thiel, E1
Hiçsönmez, G1
Tuncer, AM1
Sayli, T1
Güler, E1
Cetin, M1
Ozbek, N1
Mufti, GJ1
Cremin, P1
Flattery, M1
McCann, SR1
Daly, PA1
Verbeek, W3
Koch, P2
Hinrichs, H1
Bennett, J2
Haase, D2
Dissing, M1
Le Beau, MM1
Pedersen-Bjergaard, J1
Nagler, A1
Soni, S1
Samuel, S1
Or, R1
Solary, E3
Hecquet, B2
Caillot, D2
Brion, A3
Mahé, B1
Milpied, N2
Janvier, M3
Rochant, H3
Cordonnier, C2
Buzyn, A1
Hoang-Ngoc, L3
Stoppa, AM2
Sadoun, A2
Stamatoulas, A1
Tilly, H2
Brice, P3
Maloisel, F2
Lioure, B2
Desablens, B2
Leleu, X1
Jouet, JP1
Casassus, P1
Lepelley, P1
Hinrichs, HF1
Fonatsch, C1
Partridge, SE1
Lowdell, CP1
Veil, A1
Pignon, B1
Abgrall, JP1
Leporrier, M1
Latagliata, R1
Breccia, M1
Pulsoni, A1
Aloe Spiriti, MA1
D'Elia, GM1
Spadea, A1
Montefusco, E1
Luzi, G1
Betrò, P1
Petti, MC1
Saso, R1
Kulkarni, S1
Mitchell, P1
Treleaven, J1
Swansbury, GJ1
Mehta, J1
Powles, R1
Ashley, S1
Kuan, A1
Powles, T1
Rong, A1
Gattermann, N1
Rieth, C1
Seiter, K1
Feldman, EJ1
Sreekantaiah, C1
Pozzuoli, M1
Weisberger, J1
Liu, D1
Papageorgio, C1
Weiss, M1
Kancherla, R1
Ahmed, T1
Young, MS1
Liesveld, JL1
Miller, KB1
Lazarus, HM1
Marsh, RD1
Friedenberg, WR1
Saba, HT1
Hayes, FA1
Dewald, GW1
Wulf, GG1
Wang, RY1
Kuehnle, I1
Weidner, D1
Marini, F1
Brenner, MK1
Andreeff, M1
Goodell, MA1
de Witte, T1
Suciu, S1
Verhoef, G1
Labar, B1
Archimbaud, E1
Selleslag, D1
Ferrant, A1
Wijermans, P1
Mandelli, F1
Amadori, S1
Jehn, U1
Muus, P1
Boogaerts, M1
Zittoun, R1
Gratwohl, A1
Zwierzina, H1
Hagemeijer, A1
Willemze, R1
Körbling, M1
Hunstein, W1
Rosenthal, NS1
Farhi, DC1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015]Early Phase 155 participants (Actual)Interventional2013-03-15Completed
Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522]Phase 223 participants (Actual)Interventional2009-04-30Completed
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8[NCT00533416]Phase 114 participants (Actual)Interventional2007-09-14Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for mitoxantrone and Myelodysplastic Syndromes

ArticleYear
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
    American journal of hematology, 2017, Volume: 92, Issue:9

    Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Co

2017
Myeloid disorders after autoimmune disease.
    Best practice & research. Clinical haematology, 2019, Volume: 32, Issue:1

    Topics: Arthritis, Rheumatoid; Cyclophosphamide; Genetic Predisposition to Disease; Humans; Immunosuppressiv

2019
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
    Leukemia, 2001, Volume: 15, Issue:6

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom

2001

Trials

16 trials available for mitoxantrone and Myelodysplastic Syndromes

ArticleYear
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2014
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
    Bone marrow transplantation, 2012, Volume: 47, Issue:4

    Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell

2012
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; D

2004
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Leukemia research, 2004, Volume: 28, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Dis

2004
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tra

2004
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
    Blood, 2005, Jun-15, Volume: 105, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents;

2005
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chem

2006
Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:7

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1996
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.
    Annals of hematology, 1997, Volume: 74, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Blo

1997
Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).
    Leukemia research, 1998, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Comb

1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
    British journal of haematology, 1998, Volume: 102, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa

1998
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
    Leukemia, 1999, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation

1999
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
    Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Evalua

1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
    Advances in experimental medicine and biology, 1999, Volume: 457

    Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protoco

1999
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
    American journal of hematology, 2001, Volume: 66, Issue:1

    Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bon

2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
    Blood, 2001, Oct-15, Volume: 98, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diseas

2001

Other Studies

20 other studies available for mitoxantrone and Myelodysplastic Syndromes

ArticleYear
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
    Leukemia research, 2014, Volume: 38, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Co

2014
Cladribine in the treatment of acute myeloid leukemia.
    Leukemia research, 2014, Volume: 38, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgras

2014
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; Case-Control Stud

2017
Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.
    Transplantation, 2002, Oct-27, Volume: 74, Issue:8

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2002
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Cytarabine; Disease-Free Surviv

2004
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
    American journal of hematology, 2006, Volume: 81, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans

2006
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jan-20, Volume: 25, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Breast Neoplas

2007
Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
    Cancer genetics and cytogenetics, 2008, Jan-15, Volume: 180, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chromosomes, Human, Pair 11; Chromo

2008
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Blood, 1995, Apr-15, Volume: 85, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemot

1995
Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.
    Leukemia & lymphoma, 1994, Volume: 12, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Leukemia, My

1994
High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hematologic pathology, 1995, Volume: 9, Issue:3-4

    Topics: Adolescent; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administrati

1995
Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen.
    Annals of hematology, 1997, Volume: 74, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Fanconi A

1997
Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chromosome Inv

1998
Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1999, Volume: 11, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd

1999
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
    Leukemia & lymphoma, 2000, Volume: 36, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans;

2000
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
    British journal of cancer, 2000, Volume: 83, Issue:1

    Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl

2000
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
    British journal of haematology, 2000, Volume: 110, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubi

2000
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.
    Blood, 2001, Aug-15, Volume: 98, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Ant

2001
Combination therapy with mitoxantrone and etoposide in adult acute myelogenous leukemia.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluat

1990
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
    American journal of clinical pathology, 1991, Volume: 95, Issue:4

    Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorub

1991